Since platinum-based therapy is an effective treatment for a subset of TNBCs [22], we then decided to evaluate the ability of miR-9/si-EFEMP1-induced CAF-like cells to affect tumor cell sensitivity to the anti-cancer drug cisplatin. The gene discussed is EFEMP1; the disease is neoplasm.